European League against Rheumatism – Selected Presentation and Poster a Highlights June 11th to 13th 2013

Bibliography

• Maeda Y, Matsushita M, Yura A, et al. The fecal microbiota of rheumatoid arthritis patients differs from that of healthy volunteers and is considerably altered by treatment with biologics. Ann Rheum Dis 2013;72(Suppl 3):117
   Google Scholar
• Abdollahi-Roodsaz S, Joosten LAB, Koenders MI, et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008;118:205-16
   PubMed Web of Science ®Google Scholar
• Wu H-J, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010;32:815-27
   PubMed Web of Science ®Google Scholar
• Maeda Y, Matsushita M, Katayama M. The analysis of fecal biota in rheumatoid arthritis patients compared to healthy volunteers using bacterial rRNA-targeted reverse transcription-quantitative PCR. Ann Rheum Dis 2012;71(Suppl 3):496
   Google Scholar
• Kuchroo VK, Ohashi PS, Sator RB, Vinuesa CG. Dysregulation of immune homeostasis in autoimmune diseases. Nat Med 2012;18:42-7
   PubMed Web of Science ®Google Scholar
• Podojil JR, Miller SD. Targeting the B7 family of co-stimulatory molecules. BioDrugs 2013;27:1-13
   PubMed Web of Science ®Google Scholar
• Hecht I, McNames K, Vaknin I, et al. CGEN-15001, a novel negative co-stimulator fusion protein is effective in the collagen-induce athritis mouse model of rheumatoid arthritis. Ann Rheum Dis 2013;72(Suppl 3):119
   Google Scholar
• Avruch J, Zhou D, Fitamant J, et al. Protein kinases of the Hippo pathway: regulation and substrates. Semin Cell Dev Biol 2012;23:770-84
   PubMed Web of Science ®Google Scholar
• Nehme NT, Schmid JP, Debeurme F, et al. MST1 mutations in autosomal recessive primary immunodeficiency characterised by defective naive T-cell survival. Blood 2012;119:3458-68
   PubMed Web of Science ®Google Scholar
• Mou F, Praskova M, Xia F, et al. The Mst1 and Mst kinases control activation of rho family GTPases and thymic egress of mature thymocytes. J Exp Med 2012;4:741-59
   Web of Science ®Google Scholar
• Oravecz T, Chang WC, Jhaver KG, et al. Genetic and pharmacologic inhibition of MST1 blocks lymphocyte function and protects against inflammation and autoimmunity. Ann Rheum Dis 2013(Suppl 3):118
   Google Scholar
• Hartkamp LM, van Es IE, Fine JS, et al. BTK inhibition suppresses inflammatory cytokine production and affects gene expression in human macrophages and RA synovial tissue explants. Ann Rheum Dis 2013(Suppl 3):157
   PubMedGoogle Scholar
• Xu D, Kim Y, Postelnek J, et al. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther 2012;341:90-103
   PubMed Web of Science ®Google Scholar
• Hsu J, Gu Y, Tan SL, et al. Bruton's tyrosine kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints. Immunol Lett 2012
   PubMed Web of Science ®Google Scholar
• Holz J-B, Sargentini-Maier L, De Bruyn S. Twenty-four weeks of treatment with a novel anti-IL-6 receptor nanobody (ALX-0061) resulted in 84% ACR improvement and 58% DAS28 remission in a phase I/II study. Ann Rheum Dis 2013;72(Suppl 3):64
   Google Scholar
• Baeten DLP, Kuchroo VK. How cytokine networks fuel inflammation: interleukin-17 and a tale of two autoimmune diseases. Nat Med 2013;19:824-5
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168:412-21
   PubMed Web of Science ®Google Scholar
• Xenofon Baraliakos X, Braun J, Laurent DD, et al. Long term inhibition of interleukin (IL)-17A with secukinumab improves clinical symptoms and reduces spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis. ACR 2012;abstract 574
   Google Scholar
• Reddy M, Davis C, Wong J, et al. Modulation of CLA, IL-12R, CD40L and IL-2Rα expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol 2007;247:1-11
   PubMed Web of Science ®Google Scholar
• Cingoz O. Ustekinumab. Mabs 2009;1:216-21
   PubMed Web of Science ®Google Scholar
• Rahman P, Puig L, Gottlieb AB, et al. Ustekinumab improves physical function, quality of life and work productivity of patients with active psoriatic arthritis who were naïve to MTX, despite MTX therapy or previously treated with anti-TNFα: results from PSUMMIT 1 and PSUMMIT II. Ann Rheum Dis 2013;72(Suppl 3):671
   Google Scholar
• Ritchlin C, McInnes IB, Kavanaugh A, et al. Maintenance of efficacy and safety of ustekinumab in patients with active psoriatic arthritis despite prior conventional non-biologic and anti-TNF biologic therapy: 1 year results of the PSUMMIT2 trial. Ann Rheum Dis 2013;72(Suppl 3):48
   Google Scholar
• McInnes IB, Papp K, Puig L, et al. Safety of ustekinumab from the placebo-controlled periods of psoriatic arthritis and psoriasis clinical development programs. Ann Rheum Dis 2013;72(Suppl 3):673
   Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multi-centre, double-blind, placebo-controlled PSUMMIT1 trial. Lancet doi: 1016/S01460-6736(13)60594-2
   Web of Science ®Google Scholar
• Wang L-H, Xue Y, Liu X, et al. Preclinical development of sarilumab, the first fully human monoclonal antibody (Mab) against IL-6Rα: utilisation and value of double humaised antibody model. Ann Rheum Dis 2013;72(Suppl 3):375
   Google Scholar
• van Roy M, van de Sompel A, de Smet K, et al. ALX-0061, an anti-IL6R nanobody for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as comapred to tocilizumab. Ann Rheum Dis 2013;72(Suppl 3):375
   Google Scholar
• Moon S-J, Min J-K, Cho M-L. Rebamipide attenuates arthritis severity in experimental arthritis model via reciprocal regulation of Th17-regulatory T cells and mediating heme-oxygenase-1 via NRF2 activation. Ann Rheum Dis 2013;72(Suppl 3):197
   Google Scholar
• Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998;43(9 Suppl):5S-13S
   PubMed Web of Science ®Google Scholar
• Arakawa T, Watanabe T, Fukuda T, et al. Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine. Dig Dis Sci 1995;40:2469-72
   PubMed Web of Science ®Google Scholar
• Catlett IM, Legedza AK, Sewell L, Hoock T. The effect of VX-509, a selective oral JAK3 inhibitor, on plasma biomarkers of disease activity in patients with rheumatoid arthritis. Ann Rheum Dis 2013;72(Suppl 3):217
   PubMedGoogle Scholar
• O'Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Immunol 2013;9:173-82
   Web of Science ®Google Scholar
• van Vollenhoven RF. Small molecule compounds in development for rheumatoid arthritis. Curr Opin Rheumatol 2013;25:391-7
   PubMed Web of Science ®Google Scholar
• Vayssiere B, de Vos S, Merciris D, et al. Biological effects of the JAK1 selectibve inhibitor GLPG0634 on inflammation markers in arthritic mice. Ann Rheum Dis 2013;72(Suppl 3):201
   Google Scholar
• Yamazaki S, Morio H, Inanmi M, et al. ASP015K: a novel JAK inhibitor demonstrated potent efficacy in adjuvant-induced arthritisd model in rats. Ann Rheum Dis 2013;72(Suppl 3):197
   Google Scholar
• Zhang Y, Dees C, Beyer C, et al. Inhibition of casin kinase-2 alleviates the profibrotic effects of transforming growth factor b in systemic sclerosis. Ann Rheum Dis 2013;72(Suppl 3):128
   Google Scholar
• Orzechowska E, Kozlowska E, Staron K, Trzcinska-Danielewicz J. Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability. Oncol Rep 2012;27:281-5
   PubMed Web of Science ®Google Scholar
• Ruzzene M, Penzo D, Pinna LA. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematpoietic lineage cell-specific protein (HS1) in Jurkat cells. Biochem J 2002;364:41-7
   PubMed Web of Science ®Google Scholar
• Clara Dees C, Tomcik M, Palumbo-Zerr K, et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheum 2012;64:3006-15
   PubMed Web of Science ®Google Scholar
• Pagan MA, Bain J, Kazimierczuk Z, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J 2008;415:353-65
   PubMed Web of Science ®Google Scholar
• White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation – therapeutic opportuntiies and pharmacological challenges. Pharmacol Rev 2013;65:47-89
   PubMed Web of Science ®Google Scholar
• Lebre MC, Vergunst CE, Choi IY, et al. Why CCR2 and CCR5 blockade failed and why CCR1 blockade mights still be effective in the treatment of rheumatoid arthritis. PLoS One 2011;6:e21772
   PubMed Web of Science ®Google Scholar
• Berahovich RD, Miao Z, Wang Y, et al. Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol 2005;174:7341-51
   PubMed Web of Science ®Google Scholar
• Tak PP, Balanescus A, Tseluyko V, et al. Chemokine receptor CCR1 antagonist CCX354-C treatement for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis 2013;72:337-44
   PubMed Web of Science ®Google Scholar
• Jaen JC, Dairaghi D, Leleti M, et al. Inhibition of chemokine receptors CCR1 and CCR6 as promising therapies for rheumatoid arthritis. Ann Rheum Dis 2013;72(Suppl 3):369
   PubMedGoogle Scholar
• Dairaghi DJ, Zhang P, Wang Y, et al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. Clin Pharmacol Ther 2011;89:726-34
   PubMed Web of Science ®Google Scholar
• van Meegeren MER. Blood-induced joint damage: novel targets for therapy. Dissertation; 2012: University of Utecht. Available from: http://igitur-archive.library.uu.nl/dissertations/2012-0928-200554/UUindex.html
   Google Scholar
• Hartgring SA, Steens-Louws C, de Smet M. IL-4-10 synerkine: a novel anti-inflammatory drug to inhibit imunnopathology in rheumatic diseases. Ann Rheum Dis 2013;72(Suppl 3):371
   Google Scholar
• Guenzi E, Stroissnig H, Vierboom M, et al. ATROSAB, a humanized antibody directed against TNF-receptor 1, hold great promises for the treatment of rheumatoid arthritis. Ann Rheum Dis 2013;72(Suppl 3):451
   Google Scholar
• Zettlitz KA, Lorenz V, Landauer K, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. Mabs 2010;2:639-47
   PubMed Web of Science ®Google Scholar
• Arnett HA, Mason J, Marino M, et al. TNFα promotes prolferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001;4:1116-22
   PubMed Web of Science ®Google Scholar
• Human microbiome project. http://commonfund.nih.gov/hmp/International human microbiome consortium http://www.human-microbiome.org/ Nature special: human microbiota http://www.nature.com/nature/focus/humanmicrobiota/
   Google Scholar
• Kaddurah-Daouk R, Baillie RA, Zhu H, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One 2011;6:e25482
   PubMed Web of Science ®Google Scholar
• Grundmann O. The gut microbiome and pre-systemic metabolism: current state and evolving research. J Drug Metab Toxicol 2010;1:104
   Google Scholar
• Barbhaiya M, Solomon DH. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol 2013;25:317-24
   PubMed Web of Science ®Google Scholar
• Brown JR. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep 2013;8:1-6
   PubMed Web of Science ®Google Scholar
• Hoock T, Hogan J, Mahajan S, et al. VX-509, an orally available janus kinase 3 (JAK3) specific inhibitor, showed robust activity in pre-clinical models of aberrant immune/inflammatory function. Arthritis Rheum 2011;63(Suppl 10):1136
   PubMedGoogle Scholar
• Schall TJ, Proudfoot AEI. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 2011;11:355-63
   PubMed Web of Science ®Google Scholar
• Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168:844-54
   PubMed Web of Science ®Google Scholar
• Tak PP. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology 2012;51:600-9
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 2013;72:3-6
   PubMed Web of Science ®Google Scholar
• Wilke WS. Reply to: forget personalized medicine and focus on abating disease activity. Ann Rheum Dis 2013;e8
   Google Scholar
• van deb Broek M, Visser K, Allaart CF, Huizinga TWJ. Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol 2013;13:463-9
   PubMed Web of Science ®Google Scholar